Second Line Endovascular Treatment for Acute DVT
This study is looking at whether additional endovascular treatments are safe and effective for people with acute deep venous thrombosis (DVT), which are blood clots in deep veins. These treatments, called catheter-directed thrombolysis and mechanical thrombectomy, are used when initial blood thinner medication (anticoagulation) hasn't fully improved the DVT after one week. Catheter-directed thrombolysis uses a catheter to deliver clot-dissolving medicine directly to the clot, and mechanical thrombectomy physically removes the clot. The study will measure how well these treatments work at 30, 90, and 180 days. You may be able to join if you are between 18 and 75 years old, have acute DVT in your thigh or knee area, and are able to take blood thinners. The study is currently recruiting about 100 participants.
- Study design
- This is an interventional study aiming to enroll 100 participants to evaluate the effectiveness of endovascular treatments.
- What's involved
- Participants will be followed with repeat ultrasound (US) one week after starting DVT treatment to check their response to blood thinner medication.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 180 days to assess the long-term effectiveness of the treatments.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Second Line Endovascular Treatment in Acute DVT
At a glance
Conditions
NCT06486181
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
RUSH University Medical Center
Chicago, Illinoisstudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Bulent Arslan, MD · PRINCIPAL_INVESTIGATOR · Rush University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Efficacy of Endovascular Treatments Clinically30 days
The clinical symptoms will be evaluated to assess the efficacy of treatments treatment with Villalta score which ranges from 0 to 33 where higher score is the more severe disease The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Clinically90 days
The clinical symptoms will be evaluated to assess the efficacy of treatments treatment with Villalta score which ranges from 0 to 33 where higher score is the more severe disease The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Clinically180 days
The clinical symptoms will be evaluated to assess the efficacy of treatments treatment with Villalta score which ranges from 0 to 33 where higher score is the more severe disease The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Clinically12 months
The clinical symptoms will be evaluated to assess the efficacy of treatments treatment with Villalta score which ranges from 0 to 33 where higher score is the more severe disease The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Sonographically30 days
The thrombus burden will be evaluated to assess the efficacy of treatments treatment with Marder score which ranges from 0 to 24 where higher scores represent more severe thrombus burden. The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Sonographically90 days
The thrombus burden will be evaluated to assess the efficacy of treatments treatment with Marder score which ranges from 0 to 24 where higher scores represent more severe thrombus burden. The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Sonographically180 days
The thrombus burden will be evaluated to assess the efficacy of treatments treatment with Marder score which ranges from 0 to 24 where higher scores represent more severe thrombus burden. The scores will be compared between arms at the end of the study.
- Efficacy of Endovascular Treatments Sonographically12 months
The thrombus burden will be evaluated to assess the efficacy of treatments treatment with Marder score which ranges from 0 to 24 where higher scores represent more severe thrombus burden. The scores will be compared between arms at the end of the study.